Dutch face longer waits for new cancer drugs: 'Unacceptable for such a wealthy country'

Access to new cancer treatments in the Netherlands is declining, with only 41% of medications approved in Europe over the last four years expected to be available to patients by 2025. This represents a significant drop from the 80% availability recorded four years ago, according to the latest Patient WAIT Indicator.



